Viking Therapeutics VK2735 (GLP-1/GIP Dual Agonist) Maintenance Study: Every-Other-Week Dosing Keeps Up to 97% and Monthly Dosing Up to 90% of Weight Lost During 21-Week Induction
Viking Therapeutics reported on Tuesday, September 22, 2026 topline results from a double-blind, placebo-controlled maintenance study of VK2735, its dual GLP-1/GIP receptor agonist, in about 180 adults with a BMI of 30 or higher. After 21 weeks of weekly dosing, placebo-adjusted weight loss was 16% to 19% across VK2735 cohorts; an exploratory cohort on 17.5 mg weekly (n=13) reached about 22% weight loss from baseline at week 33. In the 12-week randomized maintenance phase, every-other-week dosing kept up to 97% of mean weight loss and monthly dosing up to 90%, compared with 61% for patients switched to placebo. Viking said gastrointestinal adverse event rates during maintenance were similar to placebo, and it plans a second part of the study to test oral maintenance regimens.